Trigone therapeutic portfolio for bladder diseases

Addressing Significant Market Opportunities With Unmet Needs

for IC/BPS

women in the USA

Interstitial Cystitis /
Bladder Pain Syndrome (IC/BPS)

  • Chronic urinary bladder pain and pressure in the pelvic area. Etiology unknown
  • Dramatically impacts quality of life
  • No viable treatment to date

for Overactive Bladder

GM $3.5B
by 2022

Overactive Bladder

  • Urgency with or without urge incontinence, frequency and nocturia
  • US – 30% woman &16% men live with OAB symptoms
  • Over 50% of patients fail to adhere to their prescribed antimuscarinic agent.

for Bladder Cancer

GM 1.14B
by 2025

BCG refractory Non-muscle Invasive Bladder Cancer (NMIBC)

  • BC – 6th most common cancer in the US ,, 4 times more common in males, found most often in age group of 75-84
  • 800,000 people suffer from BC in the USA.

Development Stage

for IC/BPS

TRG-100 is a novel, effective, and safe therapy for interstitial cystitis/ bladder pain syndrome, alleviating pain and urinary urgency as well as enhance patient compliance and improve quality of life with minimal systemic side effects.


Key benefits

  • Significantly reduced pain, urination episodes and O’Leary-Sant Interstitial Cystitis Problem Index score in patients with IC/BPS who are not responding to other therapies
  • Multimodal treatment of IC/BPS to ameliorate disease symptoms such as intense
    pain, urinary urgency, and bladder inflammation
  • Effective and durable treatment
  • Boosts patient compliance with prolonged lasting effect for two weeks and beyond

TRG-100 is highly effective with most patients experiencing more than 50% reduction in pain and alleviates urination episodes frequency throughout the day

for Overactive Bladder

TRG-120 is a novel, effective, and safe therapy for chronic Overactive Bladder, designed to reduce urinary urgency as well as enhance patient compliance and improve quality of life


TRG-120 Reduce Urination Frequency in OAB


for Bladder Cancer

TRG-140 is a treatment of patients with non-muscle invasive bladder cancer who are not responding to current standard of care (BCG).


Key benefits

  • Prolonged exposure of gemcitabine to the tumors and significantly reduce the
    risk of cancer recurrence over time
  • Constantly release the drug for long period directly onto the tumors prevents
    cancer progression (cancer getting worse)
  • Effective and safe in eradicating the NMIBC tumors for longer period

Gemcitabine therapy has superior clinical impact on recurrence and progression-free survival than mitomycin as well as BCG in individuals with high-risk non muscle invasive bladder cancer (NMIBC) diseases who have previously failed BCG.

1Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review. Investig Clin Urol. 2021 Nov;62(6):623-630.

Contact US

Interested to get in touch with us?

Fill out the form bellow

Trigone Pharma Ltd. © 2024 by Trigone Pharma

Accessibility Toolbar